All Pharma News
Imvax Completes IGV-001 Phase 2b Enrollment, Funding Round

Imvax Completes IGV-001 Phase 2b Enrollment, Funding Round
BUSINESSWIRE
21 May 2024
Share Share
Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its IGV-001

Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its IGV-001
BUSINESSWIRE
20 Nov 2023
Share Share
Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting

Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting
BUSINESSWIRE
10 Nov 2023
Share Share
Imvax Provides Corporate Update

Imvax Provides Corporate Update
BUSINESSWIRE
06 Sep 2023
Share Share
Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death

Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death
BUSINESSWIRE
08 Aug 2023
Share Share
Imvax Presents New Data at AACR 2023 Supporting the Mechanism of Action

Imvax Presents New Data at AACR 2023 Supporting the Mechanism of Action
BUSINESSWIRE
17 Apr 2023
Share Share
Imvax Announces First Patient Dosed in Ph 2b Trial of IGV-001 for Glioblastoma

Imvax Announces First Patient Dosed in Ph 2b Trial of IGV-001 for Glioblastoma
BUSINESSWIRE
27 Mar 2023
Share Share
Imvax to Present Data on Tumor-Derived Immunotherapy Platform at SITC Meeting

Imvax to Present Data on Tumor-Derived Immunotherapy Platform at SITC Meeting
BUSINESSWIRE
06 Oct 2022
Share Share
Imvax Presents Data on Whole-Tumor Derived Immunotherapeutic Platform

Imvax Presents Data on Whole-Tumor Derived Immunotherapeutic Platform
BUSINESSWIRE
29 Sep 2022
Share Share
Imvax Presents New Data on Tumor-Derived Immunotherapies in Solid Tumors at AACR

Imvax Presents New Data on Tumor-Derived Immunotherapies in Solid Tumors at AACR
BUSINESSWIRE
08 Apr 2022
Share Share